Kythera Biopharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 77   

Articles published

KYTH 35.69 +0.18 (0.51%)
price chart
Why KYTHERA Biopharmaceuticals Inc. Shares Shot Higher
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
KYTHERA Acquires Rights to ATX-101 Outside of the US and Canada From ...  MarketWatch
Kythera Regains ATX-101 from Bayer - Analyst Blog  NASDAQ
Related articles »  
KYTHERA Biopharmaceuticals Releases Third Quarter 2014 Operating Results
WESTLAKE VILLAGE, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today reported financial results for its third quarter 2014 and provided an update on recent accomplishments.
Kythera Biopharmaceuticals Price Target Cut to $59.00 by Analysts at FBR ...  sleekmoney
Kythera Biopharmaceuticals Given New $59.00 Price Target at FBR Capital ...  WKRB News
Related articles »  
What Hedge Funds Think About Kythera Biopharmaceuticals Inc (KYTH)
According to our 13F database, Partner Fund Management, managed by Christopher Medlock James, holds the biggest position in Kythera Biopharmaceuticals Inc (NASDAQ:KYTH). Partner Fund Management has a $30.2 million position in the stock, ...
Related articles »  
KYTHERA Biopharmaceuticals Announces FDA Acceptance of ATX-101 New ...
CALABASAS, Calif., July 10, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that its New Drug Application (NDA) for ATX-101 (deoxycholic acid), has been accepted for filing by the U.S.
Kythera Reports FDA Acceptance of ATX-101 NDA, PDUFA Date Set at May 13 ...  Benzinga
Related articles »  
KYTHERA Biopharmaceuticals Submits New Drug Submission to Health ...
WESTLAKE VILLAGE, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it submitted a New Drug Submission (NDS) to Health Canada seeking approval for the company's investigational drug, ...
Related articles »  
KYTHERA Biopharmaceuticals Releases Second Quarter 2014 Operating Results
KYTHERA Biopharmaceuticals, Inc. KYTH, +2.74% today reported financial results for its second quarter 2014 and provided an update on recent accomplishments.
Related articles »  
Stocks to Watch: Wageworks Inc , Silicon Graphics International Corp , Kythera ...
Bulls ran amok in Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) as the shares surged 2.25% before the noon session. The shares were trading at $37.995, up 0.835 points while the volume touched 36,226 shares.
Kythera Biopharmaceuticals Director Sells $61967 in Stock (KYTH)  WKRB News
Insider Selling: Kythera Biopharmaceuticals CEO Unloads 5994 Shares of Stock ...  Mideast Time
Related articles »  
KYTHERA Biopharmaceuticals Announces Third Quarter 2013 Operating Results
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market.
Related articles »  
Hedge Funds Are Betting On Kythera Biopharmaceuticals Inc (KYTH)
Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) was in 10 hedge funds' portfolio at the end of March. KYTH investors should be aware of an increase in support from the world's most elite money managers lately.
Company Update on High Short Interest: Enernoc Inc , Kythera ...
Kythera Biopharmaceuticals Inc (NASDAQ:KYTH): Each share of KYTHERA Biopharmaceuticals Inc is priced at $38.18, which is 32.3% below the 52-week high.